跳至主要内容
临床试验/NL-OMON33536
NL-OMON33536已完成2 期

Effect of N-acetylcysteine on thiopurine related hepatotoxicity in IBD patients - NACTOX

Vrije Universiteit Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • written informed consent; adult patients, aged between 18 and 70 years; Crohn's disease or ulcerative colitis; azathioprine, 6-mercaptopurine or 6-thioguanine therapy, Grade 1 or 2 on the CTCAE v3.0 of at least one of the following liver tests: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (AP), gamma-glutamyl transferase (GGT) or total bilirubine (Bili).

排除标准

  • Serological findings consistent with active viral hepatitis A, B, C EBV or CMV; findings suggesting auto-immune hepatitis (AIH); cholestasis; known liver diseases inlcuding: Hepatitis A, B or C, cirrhosis, AIH, primary sclerosing cholangitis, primary biliairy cirrhosis, hepatocellular carcinoma, metastatic liver disease or symptomatic cholecystolithiasis; Use of methotrexate or other chemotherapy within the last three months; use of N-acetylcysteine during thioipurine therapy; allergy to N-acetylcysteine; lactation; pregnancy; 6-TGN level >1200 pmol

研究者

相似试验